Saw Palmetto Matrix
Natural health product licensed in Canada
- Other names
- Cyto-Saw Palmetto, Saw Palmetto, Saw Palmetto Forte Matrix, Saw Palmetto HP, Saw Palmetto Matrix Forte, Saw Palmetto Matrix HP, Saw Palmetto Matrix XP, Saw Palmetto Principles, Saw Palmetto XP
- Licence holder
- Cyto-Matrix Inc.
- NPN or DIN-HM
- 80108725
- Status
- Active licence
- Licence date
- 15 March 2021
- Revision date
- 17 January 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Extract : Matériel brut sec Extraction ratio : 8:1 Dry plant equivalent : 2,000 mg | 250 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Cellulose microcristalline, Stéarate de magnésium, silice
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Hommes | minimum: 18 years | 1 Capsule | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow/incomplete voiding/frequent daytime/night time urination) associated with mild to moderate benign prostatic hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80108725
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging